TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02902809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab open-label
Description: Subcutaneous injection; fixed dose; 300 mg
Study: NCT02066662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban or Marcumar
Description: Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or Marcumar
Description: Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
Study: NCT02139410

Intervention type: PROCEDURE
Intervention: IGF-1 serum value
Description: Evaluation of IGF-1 serum value at baseline, 24 and 48 months
Study: NCT04441866

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Standard technique
Description: Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
Study: NCT02937935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protocol Guided Renal Replacement Therapy
Description: In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: On Demand Renal Replacement Therapy
Description: Patients to be randomized to the intervention as per standard of care
Study: NCT03793803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study: NCT04273971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
Study: NCT04061746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: Patients in Group A will receive a single MSCs infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Description: Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
Study: NCT03398486

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: inactivation of trigger points (TrP)
Description: A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
Study: NCT00000253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Study: NCT00421447

Intervention type: DRUG
Intervention: Anastrozole
Description: Group of women with breast cancer

Intervention type: DRUG
Intervention: Anastrozole
Description: Group of women with breast cancer
Study: NCT04746742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled Femoral Catheter (TFC) group
Description: Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoro-femoral Arteriovenous graft (FF-AVG) group
Description: Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
Study: NCT01975987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Study: NCT04529187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
Study: NCT05313100

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sugammadex
Description: At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Study: NCT04024384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
Study: NCT05544981

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice containing \~5 mmol of inorganic nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice which is nitrate-depleted
Study: NCT03170232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 35 mg tablets
Description: Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) sensor device
Description: MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metered dose inhaler (MDI) sensor device
Description: MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
Study: NCT02730897

Intervention type: PROCEDURE
Intervention: Central/Peripheral
Description: Central versus peripheral location of the primary tumor

Intervention type: PROCEDURE
Intervention: Central/Peripheral
Description: Central versus peripheral location of the primary tumor
Study: NCT03520244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Holistic Education
Description: The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
Study: NCT03742908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin/clindamycin
Description: Local implant immersion and/or breast pocket irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin/clindamycin
Description: Local implant immersion and/or breast pocket irrigation
Study: NCT01439347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection (VSLI)
Description: 2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Injection (VSI)
Description: 1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
Study: NCT02607566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Program
Description: twice weekly aerobic exercise program, 60 minutes for 12 weeks
Study: NCT03439527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Precursor Cells (MPCs), ATMP
Description: The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle Precursor Cells (MPCs), ATMP
Description: The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
Study: NCT00794820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: 25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
Study: NCT01655108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Study: NCT03855111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Acupuncture / Moxibustion
Description: Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized (Tailored) Active Acupuncture / Moxibustion
Description: Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
Study: NCT03790930

Intervention type: DIAGNOSTIC_TEST
Intervention: deep learning
Description: manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
Study: NCT02312505

Intervention type: DEVICE
Group type: OTHER
Intervention: COPFX
Description: cardiac Output by semi-invasive pulse contour analysis
Study: NCT03987568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: At the beginning of study magnetic resonance imaging MRI will be completed.
Study: NCT04665193

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Antigen Test
Description: Antigen Technology Lab-based test and Point of care test
Study: NCT02326116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trachael Preparation Education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Trachael Preparation Education
Study: NCT03708419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal diet
Description: Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
Study: NCT02728934

Intervention type: BIOLOGICAL
Intervention: Golimumab Intravenous (IV)
Description: This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: This is an observational study. Patients who will receive infliximab will be observed for 3 years.

Intervention type: BIOLOGICAL
Intervention: Biosimilar Infliximab
Description: This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
Study: NCT03167697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy
Description: Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
Study: NCT01884727

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Salt Water
Description: Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
Study: NCT03167697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: Patients will continue their usual dietary and/or protein substitute regimen (28 days).
Study: NCT04044638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance trainining
Description: Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance trainining
Description: Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
Study: NCT02246270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical Heparin
Description: Heparin bladder instillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravesical saline
Study: NCT00793585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.

Intervention type: OTHER
Group type: OTHER
Intervention: continue their usual therapy
Description: Patients will receive lifestyle modification and continue their usual therapy.
Study: NCT01884727

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ASEA water
Description: Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
Study: NCT02219243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Interpretation Training Condition 1
Description: The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Interpretation Training Condition 2
Description: The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
Study: NCT02189954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The placement according to the manufacturer's instructions
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cuff inner pressure was held below 44 mmHg
Description: cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
Study: NCT01789918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARADISE percutaneous renal denervation
Description: Intravascular ultrasound emission
Study: NCT03835728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This will be the matching placebo used in the study.
Study: NCT04331197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg
Description: Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Study: NCT03747276

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Trial Kiosk
Description: Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
Study: NCT00137735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300mg tds

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tds
Study: NCT02718963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition